Introduction {#Sec1}
============

CTCLs are a heterogeneous group of non-Hodgkin lymphoproliferative disorders characterized by accumulation and expansion of neoplastic T lymphocytes to the skin \[[@CR28]\]. MF and SS constitute two main subtypes of CTCL. While MF primarily affects the skin, SS is characterized by the presence of circulating malignant Sézary cells. Together, MF and SS account for 65--80% of CTCL cases \[[@CR9], [@CR11], [@CR23]\]. Although accumulative evidence indicates that defects in apoptosis and cell cycle control are critical in disease pathogenesis \[[@CR5], [@CR21]\], the molecular mechanism leading to these abnormalities has not been well understood yet.

The TOX gene was firstly described in 2002 \[[@CR27]\], as a part of the superfamily of high-mobility group box proteins that act as regulators of gene expression, mainly by modifying the chromatin structure \[[@CR10], [@CR27]\]. TOX mRNA is most abundant in the thymus, liver and brain \[[@CR27]\]. TOX is involved in lymphocyte maturation, and Zhang et al. demonstrated that TOX was highly and specially expressed in early MF \[[@CR31]\]. After this, several studies have confirmed that TOX is aberrantly expressed in CD4^+^ /CD8^−^ neoplastic T cells in MF and SS \[[@CR2], [@CR6], [@CR7], [@CR15], [@CR19], [@CR20], [@CR29]\], so as to be aberrantly expressed in CTCL with CD4^−^/CD8^+^ and CD4^−^/CD8^−^ phenotypes \[[@CR24]\], differentiating malignant from non-malignant skin-infiltrating T cells found in benign inflammatory dermatoses \[[@CR31]\]. Aberrant expression of TOX plays a central role in malignant survival, proliferation, and tumor formation in CTCL \[[@CR7]\]. Stable knockdown of TOX in CTCL cells has promoted apoptosis and reduced cell cycle progression, leading to less cell viability and colony-forming ability in vitro and reducing tumor growth in vivo \[[@CR7]\].

It is generally believed that abnormal gene expression is a key process in disease initiation and progression. Hut78 cell line derived from SS exhibits high expression of TOX, and TOX-deficient Hut78 cells can promote apoptosis and reduce cell cycle \[[@CR7]\], but its mechanism is not very clear. Herein, we applied RNAseq analysis to further explore transcriptional changes including expressed genes (DEGs), DEG Gene Ontology (GO) and pathways in TOX-deficient Hut78 cells.

Material and methods {#Sec2}
====================

Cell culture {#Sec3}
------------

Human CTCL cell line Hut78 (ATCC no. TIB161) was cultured in RPMI 1640 and 10%FBS as described by the American Type Culture Collection (Manassas, VA). Infected CTCL cells were cultured in the above medium plus puromycin.

Lentivirus infection {#Sec4}
--------------------

Lentivirus vector (hU6-MCS-Ubiquitin-EGFP-IRES-puromycin) and shRNA sequence were designed and synthesized by Genechem (Shanghai, China). Destination cells were infected with lentiviral supernatants, using 8 mg/ml polybrene and high virus titer for MOI ≥ 100. After 48--72 h of incubation, the supernatant was replaced by a medium containing 1 mg/ml puromycin.

RNA isolation and quantitative real-time PCR (qRT-PCR) {#Sec5}
------------------------------------------------------

Total RNA was isolated from cell pellets using TRIzol (Invitrogen, Thermo Fisher) according to the manufacturer's protocol. cDNA synthesis was performed using the GoScript™ Reverse Transcription System Kit (A5000) from Promega. qPCR reactions were performed with FastStart Universal SYBR Green Master (Rox) from Roche. The experiments were performed according to the manufacturer's instructions. The sequences of the primers used for qRT-PCR analyses are listed in Table S3. All reactions were run in triplicate. The CT values were calculated using the standard curve method.

Western blotting {#Sec6}
----------------

After lentivirus infection, HuT78 cell pellets were prepared by centrifugation at 300*g*, and then total cells were lysed in RIPA buffer (50 mM Tris, 150 mM sodium chloride, 1% Triton X-100, 0.1% sodium dodecyl sulfate, and 1% sodium deoxycholate). After removing insoluble material by centrifugation at 10,000*g* at 4 ℃ for 5 min, total protein concentration was determined using BCA assay as per manufacturer's instruction with a microplate reader. 40 μg protein was used for SDS-PAGE gel electrophoresis (Bio-Rad) and transferred onto PVDF membranes (Bio-Rad). Blocking was done with 5% milk and then the membranes were incubated with primary antibodies, anti-TOX (1:1000 HPA018322, Sigma-Aldrich) or anti-actin (1:5000, A1978, Sigma-Aldrich) overnight at 4 ℃. After washing, membranes were incubated with secondary antibodies (peroxidase-conjugated, suitable for each primary antibody) for 2 h at room temperature. The signal was detected using Bio-Rad ChemiDoc XRS + System after adding Super Signal West Pico chemiluminescence.

Apoptosis detection {#Sec7}
-------------------

The treated Hut78 cells (1 × 10^6^) using shRNA 1 construct were transferred to a 15 ml centrifuge tube. Annexin V binding buffer was added. After centrifugation at 2000 rpm for 5 min at 4 °C, the cells were washed three times and 100 µl of binding buffer, 5 µl of Annexin V-APC and 10 µl of 7-AAD stain (Thermo Fisher Scientific, Inc) were added and incubated in the dark for 25 min. Detection of apoptotic cells was performed by flow cytometry.

Cell cycle analysis {#Sec8}
-------------------

The treated Hut78 cells (1 × 10^6^) using shRNA 1 construct were collected and fixed with 75% ice-cold ethanol at 4 °C overnight and then stained with 5 µl propidium iodide (Thermo Fisher Scientific, Inc.) at room temperature for 5 min in the dark. The cell cycle distribution was analyzed by flow cytometry.

RNAseq analysis {#Sec9}
---------------

Total RNA from infected cells was harvested and extracted by using TRIzol (Invitrogen, Thermo Fisher). Agilent 2100 Bioanalyzer (Agilent RNA 6000 Nano Kit) was used to perform quality control of the total RNA samples:RNA concentration, RIN value, 28S/18S and the fragment length distribution. mRNAs were isolated from total RNA with the oligo(dT) method. The mRNAs were fragmented and then first-strand cDNA and second-strand cDNA were synthesized. cDNA fragments were purified and resolved with EB buffer for end reparation and single nucleotide A (adenine) addition. cDNA fragments were next linked with adapters. Those cDNA fragments with suitable size were selected for the PCR amplification. Agilent 2100 Bioanalyzer and ABI StepOnePlus Real-Time PCR System were used in quantification and qualification of those libraries. Equimolar pooling of libraries was performed based on qPCR values and loaded onto an Illumina Hiseq platform (BGI, China).

Results {#Sec10}
=======

Genetic silencing of Tox in Hut78 cells {#Sec11}
---------------------------------------

To investigate the transcriptional changes after TOX knockdown, two lentivirus targets were designed to knock down TOX gene in Hut78 cell line, as presented in Table S2. After lentivirus infection, RT-qPCR and Western blot were completed. TOX expression was significantly reduced in mRNA level as shown in Fig. [1](#Fig1){ref-type="fig"}a: Compared to the NC group, both sh1 and sh2 groups demonstrate significantly reduced TOX mRNA expression (*p \<*0.05). TOX protein expression was also diminished as shown in Fig. [1](#Fig1){ref-type="fig"}b with the sh1 group showing more inhibition of TOX expression than the sh2 group. Annexin V-APC/7AAD flow cytometry assay was employed to analyze cell apoptosis, and we observed that apoptotic cells were increased after knockdown of TOX as shown in Fig. [1](#Fig1){ref-type="fig"}c. The cell cycle distribution analysis showed more cells in G0/G1 phase and less cells in G2/M phase after knockdown of TOX as shown in Fig. [1](#Fig1){ref-type="fig"}d.Fig. 1Lentivirus infection knockdown TOX gene expression. TOX knockdown by 2 shRNAs (sh1 and sh2, both specific for TOX mRNA) and negative control (a non-targeting shRNA). Infected cells were selected by puromycin (1 mg/mL) for 5 days. mRNA and protein were extracted for further analysis. **a** RT-qPCR was performed between group NC, sh1 and sh2, and primer qGAPDH and TOX were used. TOX was significantly reduced in sh1 (*p* value = 0.0114, *R*^2^ = 0.8305) and sh2 (*p* value = 0.0286, *R*^2^ = 0.7371). **b** Western blotting was performed with antibodies against TOX and actin proteins. \**p* \< 0.05 by two-tailed Student's *t* test with Welch correction. Error bars indicate standard error of the mean. Data shown here are representative of at least three independent experiments. **c** Annexin V-APC/7AAD flow cytometry assay showed that apoptotic cells were increased after knockdown of TOX. **d** Annexin/PI flow cytometry assay showed that more cells in the G0/G1 phase and less cells in the G2/M phase after knockdown of TOX

DEGs after TOX knockdown {#Sec12}
------------------------

After RNAseq and reads filtering, we mapped clean reads to reference genome by using Bowtie 2 \[[@CR12]\] and then calculated the gene expression level for each sample with RSEM \[[@CR13]\], a software package for estimating gene and isoform expression levels from RNAseq data. Subsequently, we calculated Pearson correlation between all samples by using cor, performed hierarchical clustering between all samples by using hclust, performed PCA analysis with all samples using princomp, and drew the diagrams with ggplot2 with functions of R. The number of genes and transcripts in each sample are shown in Table[1](#Tab1){ref-type="table"}. We further calculated the heat map of Pearson correlation among all samples, shown in Fig. S1a. Based on the expression information, we performed box plot analysis to show the distribution of the gene expression level of each sample, so that we could observe the dispersion of the distribution (results as shown in Fig. S1b). Based on the gene expression level, we could identify the DEGs between samples or groups. MA plots were used to show the distributions of DEGs in Fig. S1. Compared to the NC group, 3897 genes were overexpressed and 2702 genes were underexpressed in group sh1 (Fig. S1c). Compared to the NC group, 2723 genes were overexpressed and 3224 genes were underexpressed in group sh2 (Fig. S1d). Taken together, after TOX knockdown, a total of 547 genes were upregulated and 649 genes were downregulated. The top 20 downregulated genes are listed in Table [2](#Tab2){ref-type="table"} and the top 20 upregulated genes are listed in Table S1. Interestingly, we found that multiple genes in the HOX gene family were downregulated in TOX-deficient Hut78 cells.Table 1Genes and transcripts statisticsSampleTotal gene numberKnown gene numberNovel gene numberTotal transcript numberKnown transcript numberNovel transcript numberNC_116,14313,262288128,21114,79513,416NC_215,47212,807266525,53713,58511,952NC_315,46812,863260525,80113,69912,102sh1_115,08912,530255924,07112,62911,442sh1_214,63912,088255121,61411,02810,586sh1_315,02312,387263623,15911,91811,241sh2_116,04013,100294028,51315,03113,482sh2_216,28113,395288630,28716,21714,070sh2_313,27811,548173020,49511,1319364*Sample* sample name, *total gene number* the amount of all genes, *known gene number* the amounts of known genes, *novel gene number* the amounts of novel genes, *total transcript number* the amount of all transcripts, *known transcript number* the amounts of known transcripts, *novel transcript number* the amounts of novel transcriptsTable 2Top 20 significantly downregulated genes after TOX knockdownGene nameGeneIDLength^a^NC-expression^b^sh1-expressionlog2 Ratio (sh1/NC)^c^*q* value^d^*p* value^e^sh2-expressionlog2 Ratio (sh2/NC)*q* value*p* valueHOXC93225152890,57416,021− 1.8379198020016,747− 2.78842703500PIGS94005264354,2177133− 2.264951439009093− 2.92914977100TXNDC16575442854301768− 4.81022317100313− 3.62211287600GPATCH454865215880472539− 1.0029776696.4747E-2447.0734E-2464285− 1.2623885700CKB115214753529984− 1.181316246.1571E-1401.7733E-141907− 2.31331771600UNC119B84747442338651210− 1.0142483977.3431E-1202.5525E-1212313− 1.093935894.2E-1892.3E-190ANP32E8161134461085.54125.58− 2.4505212961.8879E-1196.6251E-121207.8− 2.738378073.3E-1881.8E-189GBA26292637795.6460− 3.0678684337.1629E-1112.7981E-112422.83− 1.265270813.31E-508.35E-51HOXC5322216455921− 8.5482403965.00096E-962.45025E-9718− 5.3927611067.7E-1594.9E-160HOXC4322116891196281− 1.4283623852.4963E-642.18996E-65323− 2.2418440623E-1651.9E-166PRR5-ARHGAP85531581179342.3511.31− 4.2585882091.93483E-611.81269E-6297.19− 2.1698249691.43E-464.03E-47POR54472509860.3170.31− 1.6754637211.45546E-581.43585E-59216.96− 2.3406434961.6E-1251.3E-126MTPN1363193900314.210− 8.6343723173.90708E-514.87628E-520− 9.6488180281.19E-622.22E-63PMF11124311221023.19273.66− 1.2414046197.84823E-451.21854E-45641.82− 1.026066162.8E-467.97E-47CDRT42840402515243.610− 8.2672165771.33826E-412.39238E-420− 9.2816622882.29E-515.62E-52SDSL113675131132536− 2.5131579377.66449E-381.61629E-3840− 3.3756005551.42E-692.35E-70CDKN2A102912181132351− 1.0281180536.07066E-371.30831E-37191− 2.9204621572E-2099.4E-211PCSK1N273441071855238− 1.1837498773.87281E-359.09008E-36178− 2.6172799211.5E-1411.1E-142SURF168341046189.760− 7.9068191366.41566E-341.60992E-340− 8.9212648473.28E-421.05E-42ZNF616903174386295.5535.94− 2.3785269371.48496E-324.00162E-3318− 4.3905661513.72E-755.49E-76^a^Gene length; ^b^gene expression of group NC; ^c^log2 transformed fold change between NC group and sh1 group; ^d^adjusted *p* value; ^e^*p* value

GO analysis of DEGs {#Sec13}
-------------------

With DEGs, we performed Gene Ontology (GO) classification and functional enrichment. GO has three main ontologies: molecular biological function, cellular component and biological process. The GO classification results are shown in Fig. [2](#Fig2){ref-type="fig"}a, b. We used DAG (directed acyclic graph) to show the GO enrichment result. Each bar shows GO terms, and the amount of up- or down-regulated genes are shown in Fig. [2](#Fig2){ref-type="fig"}c, d. In our study, we found that TOX gene knockdown could significantly influence the cellular process, the cell growth as well as the death signal transduction, as was previously reported \[[@CR7]\]. Among most of the enriched GO terms, most DEGs were related to cellular process, biological regulation and binding process.Fig. 2GO classification of DEGs. **a** NC vs sh1; **b** NC vs sh2. GO classification and functional enrichment among molecular biological functions, cellular components and biological processes. X axis represents the number of DEGs. Y axis represents GO terms. **c** NC vs sh1; **d** NC vs sh2. GO classification of upregulated and downregulated genes. X axis represents GO terms. Y axis represents the amount of up- or down-regulated genes

Pathway analysis of DEGs {#Sec14}
------------------------

To examine the expression profile of DEGs in our result, DEGs (both upregulated and downregulated) were then subjected to the KEGG pathway enrichment analysis. More than 23% of the DEGs could be annotated. The pathway classification results comparing group NC and group sh1/sh2 are shown in Fig. [3](#Fig3){ref-type="fig"}a and supplementary Fig. S2a, and the pathway functional enrichment results are shown in Fig. [3](#Fig3){ref-type="fig"}b and supplementary Fig. S2b. The pathway functional enrichment results for up- or down-regulated genes are shown in Fig. [3](#Fig3){ref-type="fig"}c and supplementary Fig. S2c. The top ten KEGG pathways with the highest representation of the DEGs are shown in Table [3](#Tab3){ref-type="table"}. We found that most DEGs were enriched in cancer pathways (ko05200), including breast cancer (ko05224), gastric cancer (ko05226) and hepatocellular carcinoma (ko05225), and that some DEGs were also enriched in Wnt (ko04310), mTOR (ko04150) signaling pathways and pathways in regulating pluripotency of stem cells (ko04550).Fig. 3Pathway functional enrichment of DEGs between group NC and group sh1. **a** Pathway classification of DEGs; **b** Pathway functional enrichment of DEGs. **c** Pathway functional enrichment results for up- or down-regulated genes. X axis represents the term of pathways. Y axis represents the number of up- or down-regulated genesTable 3Top ten KEGG pathways with a high representation of DEGsPathwayDEGs genes with pathway annotation (5617)All genes with pathway annotation (23,480)*p* value*q* valuePathway IDPathways in cancer1235 (19.8%)3097 (13.19%)8.962456e-684.959226e-66ko05200Melanogenesis847 (13.58%)1946 (8.29%)3.684796e-641.595685e-62ko04916Wnt signaling pathway856 (13.72%)2018 (8.59%)8.728826e-592.069979e-57ko04310Breast cancer901 (14.44%)2066 (8.8%)4.650451e-693.087899e-67ko05224Gastric cancer918 (14.72%)2205 (9.39%)8.712956e-592.069979e-57ko05226Proteoglycans in cancer974 (15.61%)2264 (9.64%)2.275643e-711.888784e-69ko05205Hepatocellular carcinoma890 (14.27%)2094 (8.92%)9.088525e-622.743082e-60ko05225Hippo signaling pathway879 (14.09%)2041 (8.69%)3.845024e-641.595685e-62ko04390Signaling pathways regulating pluripotency of stem cells860 (13.79%)1999 (8.51%)2.096168e-626.959278e-61ko04550mTOR signaling pathway861 (13.8%)2026 (8.63%)1.376305e-593.807777e-58ko04150

Discussion {#Sec15}
==========

TOX is aberrantly overexpressed in CTCLs, such as MF and SS. Stable knockdown of TOX in CTCL cells reduces cell cycle progression and promotes apoptosis, leading to inhibited cell viability and colony-forming ability in vitro and suppressed tumor growth in vivo \[[@CR12]\]. After TOX gene knockdown, many genes are highly expressed, such as two cyclin-dependent kinase inhibitors (CDKNs), including CDKN1B and CDKN1C) \[[@CR15]\]. It has been reported that TOX is able to regulate cell cycle in primary Sézary cells and cutaneous T cell lymphoma, whereas TOX knockdown leads to cell cycle arrest and secondary cell death \[[@CR12], [@CR16]\]. In our study, we found that, after TOX knockdown, some proliferation and apoptosis-associated genes, such as PFKFB3, CDK5 and CKKN2A, were up- or down-regulated and most DEGs were enriched in cellular process and cancer pathways, which highlights the importance of TOX in cancer process. As we noted, both changes in apoptosis and cell cycle characteristics of the groups after gene knockdown, it is not clear if the differentially expressed genes are directly the result of interactions with TOX or the result of downstream cell cycle-dependent changes.

HOX genes, including HOXC9, HOXC4, HOXC5, HOXC8, HOXC10, HOXC11 and HOXC13, were significantly downregulated after TOX knockdown, with HOXC9 being downregulated to the highest degree. HOX genes are homeobox genes that function as transcription factors. In humans, 39 HOX genes have been assigned to 13 paralogous groups in four separate clusters termed HOXA, HOXB, HOXC and HOXD \[[@CR8]\]. HOXC9 is aberrantly expressed in breast cancer, lung cancer, body fat mass and astrocytoma \[[@CR3], [@CR8], [@CR14], [@CR22]\]. HOXC9 can induce neuronal differentiation of neuroblastoma cells \[[@CR26]\]. Wang et al. \[[@CR25]\] demonstrate that HOXC9 can directly regulate distinct sets of genes to coordinate diverse cellular processes during neuronal differentiation. This may explain why TOX knockdown will lead to less cell viability and colony-forming ability in vitro and reduce tumor growth in vivo.

Through DEGs GO analysis, we found most DEGs are related to the cellular process, biological regulation and binding process. This can explain why TOX knockdown will induce inhibited cell viability as previously reported \[[@CR7]\]. With DEGs pathway analysis applied in KEGG, we find two important tumor-related pathways, Wnt and mTOR. They are generally associated with cellular proliferation, differentiation and apoptosis in invertebrates and mammals \[[@CR4]\]. β-catenin is expressed by tumor cells in cutaneous lymphoproliferative disorders at various frequencies, and activation and accumulation of β-catenin plays an important role in the development of skin lymphomas \[[@CR1]\]. CTCL cells display mTORC1 activation in the lymphoma stage-related fashion with the highest percentage of positive cells identified at the late stage \[[@CR17]\]. Treatment with rapamycin can persistently inhibit mTORC1 signaling, and the combined inhibition of mTORC1 and MNK could totally abrogate the growth of CTCL cells \[[@CR18]\]. Taking together, these findings could help to understand the mechanism of action of TOX in CTCL and provide clues to novel therapeutics for CTCL.

Several strategies have been employed to enhance the efficacy of current treatments and to find new therapeutic options to improve survival and quality of life for patients with SS and other forms of advanced CTCL \[[@CR19], [@CR20], [@CR30]\]. TOX encodes a high-mobility group family (HMG) domain binding nuclear protein which regulates the differentiation of developing T cells. It is thought of as a molecular marker for histological diagnosis of CTCL \[[@CR6], [@CR31]\]. Our work has addressed the role of DEGs after TOX knockdown, as GO functional enrichment and pathway analysis have indicated. A limitation of this work is that findings so far are restricted to a single cell line. However, we believe the results may provide some insights into the mechanism of TOX in CTCL as well as candidate targets for therapy of CTCL in the near future.
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